Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia

A Protein kinase targeted. A number of these molecules are broad-spectrum kinase inhibitors. B Staurosporine class represents examples of broad-spectrum kinase inhibitors. PCD, preclinical development. These compounds may have progressed to phase I clinical trials.